Korea’s Top Regulator Chair Nominee Will Maintain Slow Approach To Crypto Assets

He was one of the main figures behind the Initial Coin Offering (ICO) ban and also in favor of imposing certain restrictions on crypto exchanges having …

Eun Sung-soo, the nominee to be the next chairman of the top financial regulator of South Korea, has recently talked about his future policies for crypto if he indeed gets to be in the position.

According to him, if he does get his position at the top of the Financial Services Commission (FSC), he is set to evaluate the crypto world with a slow approach.

He believes that these new assets really need more regulation in order to avoid money laundering and to be more transparent. However, he is also very cautious. He notices some degree of risk involving cryptos and has pointed at the Kimchi Premium to show how speculative cryptos can be.

The nominee also affirmed that this is not the time to fully integrate cryptos with the rest of the economy. According to him, a strong legal foundation needs to be properly established before this can happen. Doing it hastily could have side effects and he does not seem to be eager to try.

This, the local experts affirmed, can point out to a continuation of the policies that were started by Choi Jong-Ku, the current chairman who is leaving his position this week.

Choi is seen as one of the forces that stopped cryptos to be more prominent in South Korea. He was one of the main figures behind the Initial Coin Offering (ICO) ban and also in favor of imposing certain restrictions on crypto exchanges having bank accounts.

Crypto groups believe that this slow approach puts the industry in a bad position because only a few exchanges can work properly. The next chairman, however, doesn’t seem to agree with them.

Related Posts:

  • No Related Posts

Advisor Group Inc. Reduces Stock Holdings in Alteryx Inc (NYSE:AYX)

Advisor Group Inc. trimmed its holdings in shares of Alteryx Inc (NYSE:AYX) by 58.6% during the 2nd quarter, according to the company in its most …

Alteryx logoAdvisor Group Inc. trimmed its holdings in shares of Alteryx Inc (NYSE:AYX) by 58.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,719 shares of the company’s stock after selling 9,503 shares during the quarter. Advisor Group Inc.’s holdings in Alteryx were worth $732,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in Alteryx during the 2nd quarter valued at about $80,000. Penserra Capital Management LLC grew its stake in Alteryx by 70.7% during the 1st quarter. Penserra Capital Management LLC now owns 1,265 shares of the company’s stock valued at $106,000 after purchasing an additional 524 shares during the last quarter. Aperio Group LLC purchased a new stake in Alteryx during the 2nd quarter valued at about $156,000. Strs Ohio grew its stake in Alteryx by 141.9% during the 2nd quarter. Strs Ohio now owns 1,693 shares of the company’s stock valued at $184,000 after purchasing an additional 993 shares during the last quarter. Finally, Rehmann Capital Advisory Group grew its stake in Alteryx by 285.3% during the 1st quarter. Rehmann Capital Advisory Group now owns 2,354 shares of the company’s stock valued at $197,000 after purchasing an additional 1,743 shares during the last quarter. Hedge funds and other institutional investors own 66.52% of the company’s stock.

In other Alteryx news, insider Christopher M. Lal sold 5,840 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $141.90, for a total transaction of $828,696.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert Scott Jones sold 1,599 shares of the stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $86.03, for a total value of $137,561.97. The disclosure for this sale can be found here. Insiders have sold 182,006 shares of company stock valued at $20,945,223 in the last three months. Insiders own 19.82% of the company’s stock.

Several analysts have weighed in on the company. William Blair reiterated an “outperform” rating on shares of Alteryx in a research note on Wednesday, July 31st. Goldman Sachs Group began coverage on Alteryx in a research note on Friday, June 7th. They issued a “buy” rating and a $111.00 target price on the stock. Compass Point began coverage on Alteryx in a research note on Tuesday, August 13th. They issued a “buy” rating and a $150.00 target price on the stock. Cowen upped their target price on Alteryx from $112.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. Finally, DA Davidson upped their target price on Alteryx to $123.00 and gave the stock a “neutral” rating in a research note on Thursday, August 1st. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $120.16.

Shares of AYX opened at $139.94 on Tuesday. Alteryx Inc has a 52 week low of $42.23 and a 52 week high of $144.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $8.94 billion, a price-to-earnings ratio of -699.70, a PEG ratio of 56.53 and a beta of 1.24. The stock’s 50-day moving average price is $125.75 and its 200-day moving average price is $96.30.

Alteryx (NYSE:AYX) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. The company had revenue of $82.04 million during the quarter, compared to analysts’ expectations of $76.60 million. Alteryx had a negative return on equity of 1.93% and a negative net margin of 1.71%. Alteryx’s quarterly revenue was up 59.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) EPS. As a group, equities analysts anticipate that Alteryx Inc will post 0.14 EPS for the current fiscal year.

About Alteryx

Alteryx, Inc operates a self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts, data scientists, and citizen data scientists worldwide. Its software platform includes Alteryx Designer, a data profiling, preparation, blending, and analytics product used to create visual workflows or analytic processes; Alteryx Server, a server-based product for scheduling, sharing, and running analytic processes and applications in a Web-based environment; Alteryx Connect, a collaborative data exploration platform for discovering information assets and sharing recommendations across the enterprise; and Alteryx Promote, an analytics model management product for data scientists and analytics teams to build, manage, monitor, and deploy predictive models into real-time production applications.

Featured Article: What is an inverted yield curve?

Want to see what other hedge funds are holding AYX?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alteryx Inc (NYSE:AYX).

Institutional Ownership by Quarter for Alteryx (NYSE:AYX)

Receive News & Ratings for Alteryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alteryx and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Are Citizens Financial Group, Inc. (CFG) Shares Headed For A Pullback?

That is how The Vanguard Group, Inc. now has an increase position in CFG by 0.98% in the first quarter, owning 50.75 million shares of CFG stocks, …

On Friday, shares of Citizens Financial Group, Inc. (NYSE:CFG) marked $31.77 per share versus a previous $32.77 closing price. With having a -3.05% loss, an insight into the fundamental values of Citizens Financial Group, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. CFG showed a rise of 6.86% within its YTD performance, with highs and lows between $27.62 – $41.76 during the period of 52 weeks, compared to the simple moving average of -8.19% in the period of the last 200 days.

Argus equity researchers changed the status of Citizens Financial Group, Inc. (NYSE: CFG) shares from “Hold” to a “Buy” rating in the report published on July 29th, 2019. Other analysts, including Citigroup, also published their reports on CFG shares. Citigroup repeated the rating from the previous report, marking CFG under “Neutral” rating, in the report published on July 12th, 2019. Additionally, CFG shares got another “Neutral” rating from UBS, setting a target price of $38 on the company’s shares, according to the report published in July 10th, 2019. On the other hand, Citigroup Upgrade the “Buy” rating for CFG shares, as published in the report on January 9th, 2019. RBC Capital Mkts seems to be going bullish on the price of CFG shares, based on the price prediction for CFG. Another “Equal Weight” rating came from Barclays, providing a prediction for price target according to the report published in January 2nd, 2019.

Citizens Financial Group, Inc. (CFG) Analysis

The present dividend yield for CFG owners is set at 0.05, marking the return investors will get regardless of the company’s performance in the upcoming period.However, in order for the company to be able to pay its dividends, just like it is the case with Citizens Financial Group, Inc., the company needs to provide a healthy cash flow, currently at the value of 74.37. In addition, the growth of sales from quarter to quarter is recording 12.00%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of Citizens Financial Group, Inc. (CFG) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of 8.60% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while CFG is currently recording an average of 4.35M in volumes. The volatility of the stock on monthly basis is set at 2.41%, while the weekly volatility levels are marked at 2.19%with -1.94% of loss in the last seven days. Additionally, long-term investors are predicting the target price of $41.90, indicating growth from the present price of $31.77, which can represent yet another valuable research and analysis points that can help you decide whether to invest in CFG or pass.

What to Look for When Analyzing Citizens Financial Group, Inc. Shares?

Citizens Financial Group, Inc. (CFG) is based in the USA and it represents one of the well-known company operating with Financial sector. If you wish to compare CFG shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of 8.65 for Citizens Financial Group, Inc., while the value 7.89 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value 3.67 is supported by the yearly ESP growth of 33.40%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 0.40%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

Are Institutional Investors Increasing Stakes in CFG Shares?

It appears that more than several institutional investors and hedge funds decided to increase stakes in CFG in the recent period. That is how The Vanguard Group, Inc. now has an increase position in CFG by 0.98% in the first quarter, owning 50.75 million shares of CFG stocks, with the value of $1.89 billion after the purchase of an additional 493,442 shares during the last quarter. In the meanwhile, BlackRock Fund Advisors also increased their stake in CFG shares changed 1.26% in the first quarter, which means that the company now owns 26.58 million shares of company, all valued at $990.4 million after the acquisition of additional 329,919 shares during the last quarter.

SSgA Funds Management, Inc. acquired a new position in Citizens Financial Group, Inc. during the first quarter, with the value of $853.85 million, and Invesco Advisers, Inc. increased their stake in the company’s shares by 1.96% in the first quarter, now owning 370,187 shares valued at $717.13 million after the acquisition of the additional 19.25 million shares during the last quarter. In the end, LSV Asset Management increased their position by 2.10% during the first quarter, now owning 9.28 million CFG shares, now holding the value of $345.87 million in CFG with the purchase of the additional 36,539 shares during the period of the last quarter.

Related Posts:

  • No Related Posts

Revance Therapeutics (NASDAQ:RVNC) Lifted to Hold at BidaskClub

Renaissance Technologies LLC grew its holdings in Revance Therapeutics by 47.5% during the 2nd quarter. Renaissance Technologies LLC now …

Revance Therapeutics logoRevance Therapeutics (NASDAQ:RVNC) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Wednesday, July 31st, BidAskClub reports.

A number of other equities analysts also recently weighed in on RVNC. Mizuho reaffirmed a “buy” rating and set a $37.00 price target on shares of Revance Therapeutics in a research note on Wednesday, April 24th. Barclays assumed coverage on shares of Revance Therapeutics in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $28.00 target price on the stock. Finally, ValuEngine downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. Revance Therapeutics currently has a consensus rating of “Buy” and an average price target of $33.09.

NASDAQ RVNC traded up $0.12 during mid-day trading on Wednesday, reaching $10.88. 368,500 shares of the stock were exchanged, compared to its average volume of 427,449. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.59 and a current ratio of 5.59. The stock has a market capitalization of $487.33 million, a PE ratio of -2.76 and a beta of 1.00. Revance Therapeutics has a 1-year low of $10.37 and a 1-year high of $27.80. The business’s fifty day simple moving average is $12.18 and its 200 day simple moving average is $13.61.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.86). Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 79.28%. On average, analysts anticipate that Revance Therapeutics will post -3.73 EPS for the current year.

A number of hedge funds have recently made changes to their positions in RVNC. Rice Hall James & Associates LLC grew its holdings in Revance Therapeutics by 654.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 882,769 shares of the biopharmaceutical company’s stock worth $11,450,000 after acquiring an additional 765,701 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Revance Therapeutics by 47.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,330,973 shares of the biopharmaceutical company’s stock worth $17,263,000 after acquiring an additional 428,900 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Revance Therapeutics during the 2nd quarter worth $3,098,000. Nuveen Asset Management LLC acquired a new position in Revance Therapeutics during the 2nd quarter worth $2,638,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Revance Therapeutics by 197.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock valued at $4,543,000 after buying an additional 149,952 shares during the period. 95.45% of the stock is owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company’s lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Featured Article: Buyback

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revance Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Why Gulf Resources, Inc. (GURE) Dropped 4.79% in Monday’s Stock Market

Renaissance Technologies LLC shored up assets in the stock as 1761772 shares have been purchased, increasing its stake by 1.4% to 1,786,437 …

Gulf Resources, Inc. (NASDAQ:GURE) is trending higher in the market today as the company shares are trading 4.79% or 0.036 points down from last closing price of $0.76, reaching $0.7236 at last check. Any clue why there is so much of action in the GURE stock? The share price is losing for the fifth day in a row and has dropped in 3 of the last 5 days and is down -33.87% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 22,167 shares, and in total 50867 shares valued at $36807 were seen changing hands compared with 28700 shares valued at $21812 recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the GURE stock.

Gulf Resources, Inc. (GURE) shares have notched a 3-month decline of about -33.87%, but has still tumbled -2.5% year to date. By comparison, the stock sank -36.09% over the past 12 months, while it slipped -16.44% over the 1 month. The company’s market cap is around $34.48M, with its short interest ratio standing at 0.21%.

In the current trading session for GURE, the stock witnessed two major price actions, it rose to a high of $0.75 and was down as much as $0.72 at one point. The high recorded is very low when compared to their 52-week high which is $0.65. The 52-week high is now at -51.11 distance from current price. Their recent low of $1.48 represents a 11.32% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for GURE is $14.5, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Gulf Resources, Inc. earned $-1.36 per share in the trailing 12 months and has a P/E ratio of -0.53. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 18.01 and lower compared to the sector’s average of 300.41. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. GURE also has P/S multiple of 5.13. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.35x.

The company recorded an interesting insider sale transaction by the CFO on Jun 02, 2017. A Securities and Exchanges Commission filings show that Min Li sold a total of 28,182 GURE shares that day for a sum of around $49,319. The filings show that the insider now retains 90,575 shares, currently worth $65,540. Gulf Resources, Inc. (GURE) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded no shares in the business, which makes up 0% of 514,275 shares that were traded over a year. In the past 12 months, insiders have purchased 514,275 shares while the seller parted with shares.

GURE‘s last price was down -28.9% as compared to the average trading price of 50 days recorded at $1.02 while enlarging the period to 200 trading days, the average closing price was $0.9. At present, there are 45.34 million in the total number of common shares owned by the public and among those 27.35 million shares have been available to trade. The percentage of shares being held by the company management was 1.7% while institutions stake was 6.9%. The company has generated negative returns on equity over the last 12 months (-21.1%). It managed to keep its gross profit margin at 51.6% over the past 12 months.

When assessing the full upside of the GURE stock, there is another set of technicals that should be looked into and considered. Its -12.55% decline from moving average of $0.83 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.06 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

In the last five years, the EPS of the company has been roughly -36.7%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 19%. The revenue of the company has retreated at an average annualized rate of about -53.4 over the last five years. The company recently recorded an increase of 130709.9%, but this figure is rather attractive.

Let’s briefly check the hedge fund interest towards GURE stock. Citadel Advisors LLC added position in the company after it grew 253.3% or 11,905 shares of its common stock. The hedge fund now owns 42,060 shares worth $30,435, SEC documents show. Renaissance Technologies LLC shored up assets in the stock as 1761772 shares have been purchased, increasing its stake by 1.4% to 1,786,437 shares which are currently valued at $1,292,666. In addition, Renaissance Technologies LLC recently reported that it now owns 1,714,730 shares making a total of $1,240,779 based on the recent price. This refelects a change of 4.3% in their ownership.

Related Posts:

  • No Related Posts